Primaa
Primaa is a MedTech company founded in 2018 that offers an AI-based platform for automated and accurate cancer diagnosis. Their technology leverages image analysis and deep learning to enhance detection of major cancer biomarkers, guiding personalized treatment. Key products include Cleo Breast and Cleo Skin, AI assistants designed to detect breast and skin cancer respectively. The platform improves pathologists' workflow by accelerating case reviews, prioritizing cases intelligently, and increasing diagnostic precision, ultimately advancing personalized medicine and patient outcomes. Primaa has achieved CE certification, published scientific articles validating their solutions, and collaborates with leading medical organizations. Their business model is primarily SaaS, targeting pathologists and healthcare providers.
Primaa
Primaa is a MedTech company founded in 2018 that offers an AI-based platform for automated and accurate cancer diagnosis. Their technology leverages image analysis and deep learning to enhance detection of major cancer biomarkers, guiding personalized treatment. Key products include Cleo Breast and Cleo Skin, AI assistants designed to detect breast and skin cancer respectively. The platform improves pathologists' workflow by accelerating case reviews, prioritizing cases intelligently, and increasing diagnostic precision, ultimately advancing personalized medicine and patient outcomes. Primaa has achieved CE certification, published scientific articles validating their solutions, and collaborates with leading medical organizations. Their business model is primarily SaaS, targeting pathologists and healthcare providers.
TL;DR
Founded: 2018 (Paris, France)
Product focus: AI-powered digital pathology (Cleo Breast, Cleo Skin)
Regulatory milestone: Cleo Breast CE/IVDR certified
Business model: Primarily SaaS targeting pathologists and healthcare providers
Reported funding: $7.58M total (including $5.38M Series A, Nov 2024)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Digital pathology and cancer biomarker detection
Founded
2018
Industry
Biotechnology Research
Funding Track Record
$5.38M
Reported November 2024 Series A to support development and international commercialization
Company reports a first equity round in 2019 with 50 Partners
Investor Signal
“Has attracted institutional and angel investors across multiple rounds (includes 50 Partners and several other named investors in reporting)”